Ostarine (MK-2866)

Ostarine came closer to FDA approval than any SARM in history. The story of why it failed is more pharmacologically interesting than a simple 'the compound didn't work' — because it did work, by most measures.

GTx Inc. (Memphis, Tennessee) developed Ostarine in partnership with Merck during the 2000s. The target indication was cancer cachexia — the muscle wasting that affects a majority of advanced cancer patients, reduces quality of life, worsens treatment tolerance, and independently predicts mortality. The clinical development program was extensive by SARM standards: Phase 1 safety and PK studies; Phase 2 trials in cancer cachexia patients and healthy elderly; Phase 3 POWER 1 and POWER 2 trials in non-small cell lung cancer (NSCLC) patients. The Phase 2 results were genuinely positive — lean mass increased, physical function improved, and tolerability was good. GTx advanced to Phase 3 with justifiable optimism.

The Phase 3 trials ran as POWER 1 and POWER 2 — two parallel randomized controlled trials in NSCLC patients. The FDA required both lean body mass (LBM) AND physical function (stair climb power) to improve simultaneously as co-primary endpoints for both trials. Ostarine improved lean body mass in both POWER trials. But the stair climb power endpoint was variable — met in some analyses but not consistently across both trials simultaneously, and the FDA's analytical framework required both co-primaries to be met in a statistically rigorous way that Ostarine did not achieve. GTx did not submit an NDA. The company was later acquired. The regulatory outcome: Ostarine is not FDA-approved. The pharmacological outcome: the compound produced anabolic effects in cancer patients that are consistent with its proposed mechanism.

THE CENTRAL TENSION

Ostarine's central tension is not safety — it's the gap between clinical efficacy at the doses studied and the community doses that exceed them. Phase 2 trials used 1-3 mg/day; Phase 3 used doses in the 1-3 mg range. Community users take 12.5-25 mg/day — roughly 5-25x the clinical trial doses. The Phase 2 efficacy and safety data are the most favorable of any SARM, but they apply to a dose range substantially below community use. The good news: the dose gap between clinical trials and community use is smaller for Ostarine than for RAD-140 or LGD-4033, and the hepatotoxicity signal in community users is the weakest of the three compounds. For a first SARM cycle, particularly for women or older men, Ostarine remains the evidence-based conservative choice — not because it's 'safe' in an absolute sense, but because the human data is more extensive and more favorable than any other SARM.

Ostarine is a nonsteroidal, orally active AR agonist with demonstrated tissue selectivity in preclinical models: full or partial agonist in muscle and bone; partial agonist or near-neutral in prostate tissue. The mechanism is identical to the other SARMs described in this section — AR activation produces anabolic gene regulation in skeletal muscle (increased protein synthesis, decreased catabolism) and bone (increased mineralization, reduced resorption). The specific AR interaction for Ostarine produces a more modest anabolic response per dose than RAD-140 or LGD-4033 in preclinical models — lower anabolic:androgenic ratios — which aligns with the observed clinical data showing moderate lean mass gains and relatively mild HPTA suppression. This lower potency relative to other SARMs is actually part of Ostarine's safety profile — the same signaling pathway at lower intensity produces fewer systemic androgenic effects.

HPTA suppression mechanism: as with all SARMs, Ostarine activates hypothalamic and pituitary AR, suppressing GnRH, LH, and FSH. At 1-3 mg/day (Phase 2 doses), suppression is mild. At 12.5-25 mg community doses, suppression is moderate — typically less severe than RAD-140 or LGD-4033 at equivalent doses, but present. Testosterone values during community Ostarine cycles typically fall to the 200-400 ng/dL range at 20-25 mg/day — lower than normal but generally not as severely suppressed as the 100-250 ng/dL commonly seen with RAD-140 at community doses.

Ostarine produces the mildest HPTA suppression of the commonly used community SARMs (Ostarine, LGD-4033, RAD-140). At Phase 2 clinical doses (1-3 mg/day), testosterone suppression was not a clinically significant finding. At community doses (12.5-25 mg/day): testosterone typically falls to 200-400 ng/dL at 20-25 mg/day (reduced but not severely hypogonadal compared to the 100-250 ng/dL seen with RAD-140 at community doses). Short cycles (4-6 weeks) at 12.5 mg may recover without formal PCT in men with robust baseline testosterone — many users report recovery within 4-6 weeks without SERM PCT after mild Ostarine cycles. However: longer cycles (8 weeks), higher doses (25 mg+), or individual variation can produce more significant suppression requiring PCT. The prudent default is PCT after any cycle >6 weeks or >12.5 mg/day.

Context

Dose

Duration

PCT

Notes

First SARM cycle (men)

12.5-20 mg/day oral

6-8 weeks

Tamoxifen 20 mg/day x 4 weeks if >6 wks or >12.5 mg

Conservative choice for first cycle; mild suppression; best safety database in class

Body recomposition

15-25 mg/day oral

6-8 weeks

Tamoxifen 20 mg/day x 4-6 weeks

Ostarine used primarily for body recomposition (fat loss + lean mass preservation)

Women

5-12.5 mg/day oral

4-6 weeks

Typically not required; allow 8-12 wks for menstrual cycle recovery if disrupted

Lowest virilization risk of SARM class; start at 5 mg; maximum 12.5 mg; 6 week maximum

Injury recovery / joint support

12.5-20 mg/day oral

6-8 weeks

As above

Community reports consistent joint health benefit; mechanism unclear; may relate to AR-mediated collagen synthesis

Ostarine has produced multiple athlete doping violations across sports. The most prominent: Jonas Brodin (NHL defenseman, Minnesota Wild) tested positive for Ostarine in 2022, receiving a 20-game suspension under the NHL/NHLPA Performance Enhancing Substances Program. Brodin's case was notable because it involved a positive test from a supplement contamination claim — a defense not accepted in this context. Other Ostarine doping cases have been documented in cycling, track and field, and boxing. WADA S1.2 classification (Other Anabolic Agents) means absolute prohibition in competition and out-of-competition. Detection methodology: LC-MS/MS detecting parent compound and metabolites; detection window estimated at 1-3 weeks for parent compound; some metabolites potentially detectable longer. The WADA World Anti-Doping Code explicitly lists enobosarm (Ostarine) in its examples of prohibited S1 agents.

Feature

Ostarine (MK-2866)

LGD-4033

RAD-140

Phase 2+ clinical data

Most extensive — Lancet Oncology 2013; JCSM 2011; Phase 3 POWER trials

Basaria 2013 Phase 1 + VK5211 Phase 2 hip fracture

LoRusso 2022 Phase 1 in cancer — 59% elevated AST

Clinical doses studied

1-3 mg/day (Phase 2); community 5-25x higher

0.1-1 mg/day (Phase 1); community 5-200x higher

Therapeutic oncology doses (Phase 1 only)

Hepatotoxicity signal

Smallest — minimal in Phase 2 trials; few case reports

One published DILI case at 10 mg/day

Largest — 6+ case reports; one near-transplant; 59% elevated AST in Phase 1

HPTA suppression severity

Mildest at equivalent doses

Moderate

Most significant

PCT requirement

Optional for mild cycles (<6 wks, <12.5 mg); required for longer/higher

Required every cycle

Required every cycle

Anabolic potency

Moderate — best for recomposition

High — best for bulk

Highest — most potent SARM

Women's use

Best choice in class — lowest virilization risk at 5-12.5 mg

Higher virilization risk

Higher virilization risk

Athlete doping violations

Jonas Brodin (NHL 2022); cycling; T&F

Canelo Álvarez (2018); NRL players

Fewer high-profile cases; community use higher

• What is the safety profile at community doses (12.5-25 mg/day) in healthy adults? All controlled trial data is at 1-3 mg/day. No Phase 2 or 3 trial has studied the community dose range in a controlled setting.
• Will any pharmaceutical entity pursue Ostarine or a derivative for approval now that GTx has been acquired? Several companies have continued SARM development; the cancer cachexia indication remains unmet.
• What is the actual incidence of hepatotoxicity in community users at 12.5-25 mg/day? The case report literature is sparse — but SARM hepatotoxicity is likely underreported due to users not disclosing SARM use to physicians.
• Is the joint health benefit reported by many community Ostarine users (improved joint comfort, connective tissue recovery) pharmacologically real? A plausible AR-mediated collagen synthesis mechanism exists; no controlled trial has tested this in the orthopedic context.

Dobs AS, Boccia RV, Croot CC, et al. (2013). Effects of enobosarm on muscle wasting and physical function in patients with cancer. Lancet Oncology. 14(4):335-345. doi:10.1016/S1470-2045(13)70055-X. [Phase 2 RCT; n=159; 1 and 3 mg/day; 16 weeks; LBM +1.5 and +1.3 kg vs +0.1 placebo; good tolerability; the primary human efficacy evidence for Ostarine.]

Dalton JT, Barnette KG, Bohl CE, et al. (2011). The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women. Journal of Cachexia, Sarcopenia and Muscle. 2(3):153-161. doi:10.1007/s13539-011-0019-z. [Phase 2; healthy elderly; 3 mg/day; 12 weeks; significant LBM and physical function improvement; good tolerability.]

Crawford J, Prado CM, Johnston MA, et al. (2016). Study design and rationale for the Phase 3 clinical development program of enobosarm (POWER trials). Current Oncology Reports. 18(6):37. [Phase 3 POWER 1 and 2 design rationale; co-primary endpoint framework explanation; context for why Phase 3 did not result in NDA submission.]

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institutes of Health. Selective Androgen Receptor Modulators (SARMs). Updated September 20, 2025. [Most current NCBI review of SARM hepatotoxicity; notes case reports for Ostarine exist but series is smaller and less severe than RAD-140.]

Ostarine is the most evidence-supported SARM for community use and the most appropriate choice for first-cycle users, women, and anyone prioritizing evidence over maximum potency.

The honest summary: Ostarine has the most clinical trial data of any SARM at therapeutically relevant doses, the most favorable overall safety profile in controlled trials, the mildest HPTA suppression in the class, and the smallest published hepatotoxicity series. The Phase 3 regulatory near-miss — the compound produced anabolic effects in cancer patients but could not meet a demanding co-primary statistical threshold simultaneously in both trials — confirmed the mechanism without producing FDA approval. The community uses it at doses 5-25x the clinical trial range, which means the excellent Phase 2 safety data should not be applied uncritically to community protocols. Liver monitoring and HPTA monitoring remain appropriate. Within the SARM class, Ostarine is the conservative, evidence-based choice — recommended for first cycles, women, older adults, and anyone for whom the hepatotoxicity risk of RAD-140 is the primary concern.